Teams and organizations that rely solely on the HR function for succession planning are doing themselves a disservice, write Joy Taylor and Kim Lehman.
The significant scale that is necessary to break into the healthcare marketplace poses the greatest barrier to entry for women entrepreneurs. Shaleta Dunn outlines strategies that aspiring businesswomen can adopt to foster their success.
Outdated processes and technologies make it difficult for organizations to customize materials without going through repetitive review cycles. Jason Sundberg outlines how two companies addressed these challenges with a combination of modern cloud technology, disciplined process design, and careful change management.
Gary Lyon explores the role and impact of three elements of marketing planning that drive business success: Segmentation, Targeting, and Positioning.
As manufacturers look to commercialize new medicines, it is important to evaluate partners that can provide a fully integrated offering aligned to product performance goals and offer a seamless customer experience.
Industry needs to realize the potential that new treatments and technologies hold and put skills at the top of its collective agenda, write Ian Marison and Peter Levison.
AI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous, writes Margaretta Colangelo.
Strategies and recommendations for driving value in today’s AI-enhanced prescribing environment.
AI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous, writes Margaretta Colangelo.
Weighing the benefits of a deeper quantitative review for pharma.
Weighing the benefits of a deeper quantitative review for pharma.
Shrujitha Ramanujam outlines Unmetric's analysis of pharma's social media activity on LinkedIn and Facebook.
The story of how AI is improving all aspects of life science is still being written. But AI’s future impact on patients’ daily health will be informed and influenced by the work being realized today, writes Opinder Bawa.
Findings support the belief that today’s pharma finance teams should be engaged across all functional areas, including regulatory, supply chain, manufacturing, and commercial. What does that mean for current and future CFOs in the industry?
A discussion with Pam Cheng, executive vice president of Operations, Technology at AstraZeneca about making the transition into a Fortune 500 C-Suite role and leadership advice for success.
Repurposing existing technology to alleviate traditional ‘pain points’ in ensuring clinical investigator payments transparency
How engaging with digital influencers holds the key for medical affairs.
Greg Flynn discusses the advantages, challenges and possible future of CCOs and outlines their role in effective sales strategy development.
Diversity and inclusion shouldn’t be something that companies have to work hard at, writes Chris Coe.
Preserving positive ROI amid healthcare’s innovation explosion.
Opinion remains divided regarding how aggressively MS should be treated. Some neurologists believe in the “treat early, treat aggressively” approach, whilst others prefer to “save” HE therapies until the more traditional platform therapies have failed.
Creating an IP portfolio strategy that includes R&D, in-licensing, out-licensing, and mergers and acquisitions can help businesses stay ahead of the competition.
Specialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Specialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Specialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?